Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist.

Strikingly, BCY12491 caused highly significant increases in PD-L1, programmed cell death 1 and CTLA-4 mRNA levels ( figure 5E ), consistent with immune pressure on the tumor and the activation of a T cell response.

also in 132,142 other papers